Guggenheim Upgrades ServiceNow, Salesforce, and Check Point to Buy Amid 2026 Software Sell-Off
Strong upside potential in high-quality names.
Already have an account? Sign in.
Strong upside potential in high-quality names.
Blair raised its rating on PYXS following updated Phase 1 results for MICVO, citing 39% response rate, 9.2-month durability, and Phase 3 plans.
Celldex’s Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications.
Intuit cut its full-year growth outlook and sold Mailchimp, sending shares down sharply as investors reacted to slower expected growth.
Be the first to know when deals break, stocks move, or biotech headlines hit.